In vivo gene delivery for development of mammalian models for Parkinson's disease.
about
Gene-based therapy of Parkinson's Disease: Translation from animal model to human clinical trial employing convection enhanced deliveryPresynaptic dopaminergic compartment determines the susceptibility to L-DOPA-induced dyskinesia in ratsDifferential transduction following basal ganglia administration of distinct pseudotyped AAV capsid serotypes in nonhuman primatesProposed Motor Scoring System in a Porcine Model of Parkinson's Disease induced by Chronic Subcutaneous Injection of MPTP.Neuron-to-neuron α-synuclein propagation in vivo is independent of neuronal injuryNTS-Polyplex: a potential nanocarrier for neurotrophic therapy of Parkinson's diseaseAnimal models of Parkinson's disease progressionImmune-directed gene therapeutic development for Alzheimer's, prion, and Parkinson's diseases.Regenerative medicine for Parkinson's disease.How can rAAV-α-synuclein and the fibril α-synuclein models advance our understanding of Parkinson's disease?Comparison of transduction efficiency of recombinant AAV serotypes 1, 2, 5, and 8 in the rat nigrostriatal systemEfficient and stable transduction of dopaminergic neurons in rat substantia nigra by rAAV 2/1, 2/2, 2/5, 2/6.2, 2/7, 2/8 and 2/9.Combined application of neutrophin-3 gene and neural stem cells is ameliorative to delay of denervated skeletal muscular atrophy after tibial nerve transection in rats.Modification of the neurotrophin-3 gene promotes cholinergic neuronal differentiation and survival of neural stem cells derived from rat embryonic spinal cord in vitro and in vivo.Patented therapeutic RNAi strategies for neurodegenerative diseases of the CNS
P2860
Q26851517-781BC40D-C373-41EB-B5B8-7A504B2610B1Q33628372-E9C5BE64-8B13-44AC-B2AB-33A75A8B489DQ33731243-BD8E5200-BCB2-41B4-B0F5-BE0211BE62B7Q34241599-B2750F42-A0EF-4C4F-893C-D3E8113DF5B2Q35206648-2C1347CB-E056-4174-9BF4-6C85ACA707FFQ36089698-B483BB10-D59B-423D-8D72-1CDCD3147D34Q36924624-6C79A745-5082-4445-B5A3-67E3C5CF5BCDQ37302816-3DC408DB-DAA1-40AC-AAD9-5710FDBBBD81Q38369065-D956B1AE-364F-430D-896D-2F75956920A6Q38790881-9C2E03B6-31A7-4B12-928A-07170C387B00Q41340219-D7C41177-C685-4269-B764-66E6D9D9B6D1Q43577652-0CFA2636-D31F-4027-82D4-FCE0F033F597Q43755985-B2F022B7-5C13-4078-83BD-94A25FC47D53Q54292579-6B075481-513C-4F6D-A4B1-E23B07CBB6AFQ57675694-ACE71BFB-0CE7-41AB-B8E8-266D5C69951B
P2860
In vivo gene delivery for development of mammalian models for Parkinson's disease.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 22 September 2007
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
In vivo gene delivery for development of mammalian models for Parkinson's disease.
@en
In vivo gene delivery for development of mammalian models for Parkinson's disease.
@nl
type
label
In vivo gene delivery for development of mammalian models for Parkinson's disease.
@en
In vivo gene delivery for development of mammalian models for Parkinson's disease.
@nl
prefLabel
In vivo gene delivery for development of mammalian models for Parkinson's disease.
@en
In vivo gene delivery for development of mammalian models for Parkinson's disease.
@nl
P2093
P1476
In vivo gene delivery for development of mammalian models for Parkinson's disease
@en
P2093
Ayse Ulusoy
Deniz Kirik
Stephan Hermening
P304
P356
10.1016/J.EXPNEUROL.2007.09.011
P407
P577
2007-09-22T00:00:00Z